A randomized, controlled trial of methylprednisolone or naloxone in the treatment of acute spinal-cord injury. Results of the Second National Acute Spinal Cord Injury Study
- PMID: 2278545
- DOI: 10.1056/NEJM199005173222001
A randomized, controlled trial of methylprednisolone or naloxone in the treatment of acute spinal-cord injury. Results of the Second National Acute Spinal Cord Injury Study
Abstract
Studies in animals indicate that methylprednisolone and naloxone are both potentially beneficial in acute spinal-cord injury, but whether any treatment is clinically effective remains uncertain. We evaluated the efficacy and safety of methylprednisolone and naloxone in a multicenter randomized, double-blind, placebo-controlled trial in patients with acute spinal-cord injury, 95 percent of whom were treated within 14 hours of injury. Methylprednisolone was given to 162 patients as a bolus of 30 mg per kilogram of body weight, followed by infusion at 5.4 mg per kilogram per hour for 23 hours. Naloxone was given to 154 patients as a bolus of 5.4 mg per kilogram, followed by infusion at 4.0 mg per kilogram per hour for 23 hours. Placebos were given to 171 patients by bolus and infusion. Motor and sensory functions were assessed by systematic neurological examination on admission and six weeks and six months after injury. After six months the patients who were treated with methylprednisolone within eight hours of their injury had significant improvement as compared with those given placebo in motor function (neurologic change scores of 16.0 and 11.2, respectively; P = 0.03) and sensation to pinprick (change scores of 11.4 and 6.6; P = 0.02) and touch (change scores, 8.9 and 4.3; P = 0.03). Benefit from methylprednisolone was seen in patients whose injuries were initially evaluated as neurologically complete, as well as in those believed to have incomplete lesions. The patients treated with naloxone, or with methylprednisolone more than eight hours after their injury, did not differ in their neurologic outcomes from those given placebo. Mortality and major morbidity were similar in all three groups. We conclude that in patients with acute spinal-cord injury, treatment with methylprednisolone in the dose used in this study improves neurologic recovery when the medication is given in the first eight hours. We also conclude that treatment with naloxone in the dose used in this study does not improve neurologic recovery after acute spinal-cord injury.
Comment in
-
Treatment of spinal-cord injury.N Engl J Med. 1990 May 17;322(20):1459-61. doi: 10.1056/NEJM199005173222009. N Engl J Med. 1990. PMID: 2184359 Clinical Trial. No abstract available.
-
A randomized, controlled trial of methylprednisolone or naloxone in the treatment of acute spinal-cord injury.N Engl J Med. 1990 Oct 25;323(17):1207-9. doi: 10.1056/NEJM199010253231712. N Engl J Med. 1990. PMID: 2278580 Clinical Trial. No abstract available.
Similar articles
-
Pharmacological treatment of acute spinal cord injury: current status and future projects.J Emerg Med. 1993;11 Suppl 1:43-8. J Emerg Med. 1993. PMID: 8445202 Clinical Trial.
-
Treatment of acute spinal cord injury with methylprednisolone: results of a multicenter, randomized clinical trial.J Neurotrauma. 1991 Jul;8 Suppl 1:S47-50; discussion S51-2. J Neurotrauma. 1991. PMID: 1920461 Clinical Trial.
-
Administration of methylprednisolone for 24 or 48 hours or tirilazad mesylate for 48 hours in the treatment of acute spinal cord injury. Results of the Third National Acute Spinal Cord Injury Randomized Controlled Trial. National Acute Spinal Cord Injury Study.JAMA. 1997 May 28;277(20):1597-604. JAMA. 1997. PMID: 9168289 Clinical Trial.
-
Secondary injury mechanisms in acute spinal cord injury.J Emerg Med. 1993;11 Suppl 1:13-22. J Emerg Med. 1993. PMID: 8445198 Review.
-
[Methylprednisolone in the treatment of acute spinal cord injury has become more and more questioned].Lakartidningen. 2005 Jun 13-26;102(24-25):1887-8, 1890. Lakartidningen. 2005. PMID: 16044768 Review. Swedish.
Cited by
-
Ultra-early (≤8 hours) surgery for thoracolumbar spinal cord injuries: A systematic review and meta-analysis.N Am Spine Soc J. 2023 Oct 5;16:100285. doi: 10.1016/j.xnsj.2023.100285. eCollection 2023 Dec. N Am Spine Soc J. 2023. PMID: 37942310 Free PMC article. Review.
-
Continued development of azithromycin as a neuroprotective therapeutic for the treatment of spinal cord injury and other neurological conditions.Neural Regen Res. 2021 Mar;16(3):508-509. doi: 10.4103/1673-5374.293146. Neural Regen Res. 2021. PMID: 32985477 Free PMC article. No abstract available.
-
Early versus delayed decompression for traumatic cervical spinal cord injury: results of the Surgical Timing in Acute Spinal Cord Injury Study (STASCIS).PLoS One. 2012;7(2):e32037. doi: 10.1371/journal.pone.0032037. Epub 2012 Feb 23. PLoS One. 2012. PMID: 22384132 Free PMC article.
-
Prussian blue nanotechnology in the treatment of spinal cord injury: application and challenges.Front Bioeng Biotechnol. 2024 Sep 11;12:1474711. doi: 10.3389/fbioe.2024.1474711. eCollection 2024. Front Bioeng Biotechnol. 2024. PMID: 39323764 Free PMC article. Review.
-
Spinal cord injury: a review of current therapy, future treatments, and basic science frontiers.Neurochem Res. 2013 May;38(5):895-905. doi: 10.1007/s11064-013-0991-6. Epub 2013 Mar 6. Neurochem Res. 2013. PMID: 23462880 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical